Also known as: Rigel
The FDA has approved Pfizer's BRAFTOVI for BRAF V600E metastatic colorectal cancer and VEPPANU for ESR1 mutated breast cancer. The oncolytic virus cancer therapy pipeline expands with over 120 companies developing 125+ drugs. Positive late-stage data for other Pfizer oncology programs was also reported.
April 2 biotech value screen names Bicycle Therapeutics, Novavax, and PTC Therapeutics. Novavax earned an A Value Grade; February screens included Arcturus, Emergent, Puma, Rigel, and Sutro.
Monthly patent reviews from April through December 2025 highlight notable drug discovery IP disclosures across targeted protein degradation, small molecule modulators, and emerging therapeutic targets in oncology, immunology, and neurology.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07704658 |
Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors |
RECRUITING | PHASE4 |
| NCT07486713 |
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies |
RECRUITING | PHASE4 |
| NCT07471841 |
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax |
RECRUITING | PHASE2 |
| NCT06597734 |
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm |
WITHDRAWN | PHASE2 |
| NCT06566742 |
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. |
RECRUITING | PHASE2 |
| NCT06161974 |
Study of Olutasidenib and Temozolomide in HGG |
RECRUITING | PHASE2 |
